磁共振引导的风险适配主动监测用于前列腺癌:大型队列研究更新结果
该临床队列纳入2000年2月至2023年7月间开始主动监测的前列腺癌患者,要求Gleason评分≤3+4、PSA<20 ng/ml且至少两次MRI扫描。主要结局为无事件生存(EFS),定义为组织学升级至GS≥4+3或转为治疗。中位随访64个月,5年EFS率在MRI不可见GS 3+3组为91%,MRI可见GS 3+3组为71%,MRI不可见GS 3+4组为70%,MRI可见GS 3+4组为44%。
要点
- 基线MRI可见性和Gleason 4模式与主动监测中治疗转换和组织学升级相关
- MRI不可见GS 3+3患者5年无事件生存率最高(91%)
- MRI可见GS 3+4患者5年无事件生存率最低(44%)
核心结论
- 基线MRI可见性和次级Gleason模式4与MRI引导主动监测中进展至治疗及原发性Gleason模式4相关。
研究设计与样本
- 临床队列研究,纳入2000年2月至2023年7月开始主动监测的患者,要求Gleason评分≤3+4、PSA<20 ng/ml且至少两次MRI扫描,共1150例,中位随访64个月(四分位数:32,107)。
主要发现
- 基线时412例(36%)为GS 3+4,627例(55%)有MRI可见病灶,201例(17%)为MRI可见Gleason 3+4疾病。
- 5年无事件生存率:MRI不可见GS 3+3为91%(95%CI:88-94%),MRI可见GS 3+3为71%(65-78%),MRI不可见GS 3+4为70%(63-78%),MRI可见GS 3+4为44%(35-54%)。
- 487例患者进行了随访活检,其中74例活检超过一次,组织学升级至GS≥4+3不常见,发生于67例患者。
- 10例患者进展至淋巴结或骨转移,且仅发生于拒绝推荐随访MRI和/或活检的患者。
关键数值与推荐
- 主动监测纳入标准:Gleason评分≤3+4、PSA<20 ng/ml、至少两次MRI扫描。
- 主要结局无事件生存定义为组织学升级至GS≥4+3或转为治疗。
- 风险分层依据基线MRI可见性和Gleason模式4。
临床怎么用
- 对于MRI引导主动监测的前列腺癌患者,应依据基线MRI可见性和Gleason 4模式进行风险分层。
- MRI可见GS 3+4患者进展风险较高,需密切监测。
- 应强调按推荐进行随访MRI和活检,以避免转移进展。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Magnetic resonance imaging (MRI)-led active surveillance (AS) for prostate cancer uses prostate-specific antigen (PSA) and MRI for regular monitoring with biopsy only when indicated by changes in MRI or PSA density. METHODS: This clinical cohort, which started AS between February 2000 and July 2023, includes those with (1) Gleason score (GS) ≤3 + 4, (2) PSA <20 ng/ml, and (3) at least two MRI scans. The primary outcome was event-free survival (EFS) defined as histological upgrade to GS ≥4 + 3 or transition to treatment. Patients were risk stratified by baseline MRI visibility and Gleason pattern 4, and Kaplan-Meier curves were used to compare groups. KEY FINDINGS AND LIMITATIONS: The cohort consisted of 1150 patients with a median follow-up of 64 mo per person overall (quartiles: 32, 107). At baseline, of these 1150 patients, 412 (36%) had GS 3 + 4, 627 (55%) had an MRI-visible lesion, and 201 (17%) had MRI-visible Gleason 3 + 4 disease. The EFS rate at 5 yr was 91% (95% confidence interval: 88-94%) for nonvisible GS 3 + 3, 71% (65-78%) for MRI-visible GS 3 + 3, 70% (63-78%) for nonvisible GS 3 + 4, and 44% (35-54%) for MRI-visible GS 3 + 4. A total of 487 patients had follow-up biopsies, with 74 having more than one, and histological upgrade to GS ≥4 + 3 was uncommon, occurring in 67 patients. Progression to nodal or bone metastases occurred in ten patients and only in those who had declined the recommended follow-up MRI and/or biopsies. Thirty patients chose treatment despite having stable characteristics, and 31 were lost to follow-up. CONCLUSIONS AND CLINICAL IMPLICATIONS: MRI visibility and secondary Gleason pattern 4 at baseline are associated with progression to treatment and to primary Gleason pattern 4 during MRI-led AS.
引用
- Englman C, Adebusoye B, Maffei D, et al. Magnetic Resonance Imaging-led Risk-adapted Active Surveillance for Prostate Cancer: Updated Results from a Large Cohort Study. Eur Urol. 2025. PMID: 40436709. doi:10.1016/j.eururo.2025.03.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。